Gulhati et al. demonstrate therapeutic efficacy for combinatorial administration of 41BB agonist, LAG3 antagonist and a CXCR1/2 inhibitor in murine pancreatic cancer models, resulting in a remodeled tumor microenvironment.
- Pat Gulhati
- Aislyn Schalck
- Ronald A. DePinho